At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 359 enrolled

Drug / intervention

MK0557drug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00092872

NCT00092872Phase 3Completed

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of MK0557 in Obese Patients

Merck Sharp & Dohme LLC·interventional·Posted Sep 28, 2004·Updated Jan 30, 2015

In Brief

A Phase 3 clinical trial evaluating MK0557 for Obesity. Completed, enrolled 359 participants.

This is a 1-year study to assess the safety, tolerability, and efficacy of an investigational drug in obese patients after a very low calorie diet.

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsObesity

Countries--

Collaborators--

Phase 3CompletedFinished

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartNov 2003

First PostedSep 2004

Primary CompletionFeb 2005

TodayJul 2026

First PostedSep 28, 2004

Enrollment StartNov 1, 2003

Primary CompletionFeb 1, 2005

TodayJul 2, 2026

Enrollment to primary: 1.3 yearsPosted 21.8 years ago

MK0557drug